By InvitationNot Applicable

Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients

Russia54 participantsStarted 2025-03

Plain-language summary

The goal of this clinical trial is to evaluate the efficacy of an automated chatbot system in improving quality of life, reducing depression and anxiety, and decreasing visceral sensitivity in patients with Irritable Bowel Syndrome. The main research question is: Is an automated chatbot as effective for patients with IBS as standard care? Participants will be asked to complete online surveys to assess quality of life, symptoms of depression and anxiety, and visceral sensitivity before and after the intervention.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults ≥18 years; * Diagnosed with IBS; * Signed informed consent. Exclusion Criteria: * Age under 18 years; * Pregnant individuals; * Patients with cognitive or sensory impairments that hinder understanding of questions in surveys, scales, or instruments used in the study; * Patients unable to use a chatbot; * Patients currently participating in any other clinical trial or experimental study; * Patients with psychotic symptoms; * Patients with other conditions that may influence the endpoints of the current study.

What they're measuring

Change the Health-related quality of life in IBS

Timeframe: 8 weeks

Change the Health-related quality of life in IBS

Timeframe: 8 weeks

Trial details

NCT IDNCT06837064

SponsorResearch and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05

View on ClinicalTrials.gov More Irritable Bowel Syndrome trials